R. Scalco
Roche (Switzerland)(CH)Ministry of Education(BR)Coordenação de Aperfeicoamento de Pessoal de Nível Superior(BR)National Hospital for Neurology and Neurosurgery(GB)University College London(GB)
Publications by Year
Research Areas
Neurogenetic and Muscular Disorders Research, Glycogen Storage Diseases and Myoclonus, RNA modifications and cancer, Neurological disorders and treatments, Genetic Neurodegenerative Diseases
Most-Cited Works
- → Risdiplam in Type 1 Spinal Muscular Atrophy(2021)395 cited
- → Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls(2021)268 cited
- → Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial(2021)209 cited
- → Rhabdomyolysis: a genetic perspective(2015)149 cited
- → Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines(2021)125 cited
- → Exertional rhabdomyolysis: physiological response or manifestation of an underlying myopathy?(2016)113 cited